Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a high-dose form of a supplement called Coenzyme Q10 (2,400 mg per day) compared to a placebo (a dummy treatment with no active ingredient) in people with Huntington's disease. A total of 609 people took part — 303 in the Coenzyme Q10 group and 306 in the placebo group. The trial ran for 60 months (five years). The main thing being measured was a combined score that took into account both how long participants survived and how well they could manage everyday tasks and independent living — this was called a "joint rank" score. The reported data shows that on the main joint rank measure, the Coenzyme Q10 group received an average rank of 303.3 and the placebo group received an average rank of 306.7 — figures that were very close together. For the secondary measures, both groups showed declines over five years across all areas tested. The reported data shows that scores measuring ability to manage daily activities (Total Functional Capacity) fell by an average of 4.53 points in the Coenzyme Q10 group and 4.76 points in the placebo group (on a 0–13 scale). A daily task checklist (0–25 scale) dropped by 7.93 versus 8.02 points respectively. An independence scale (0–100) fell by 26.30 points in the Coenzyme Q10 group and 24.86 in the placebo group. A motor (movement) skills score (0–124, higher meaning more impairment) increased by 18.06 versus 19.18 points. Scores measuring behavioural symptoms increased by 1.39 versus 1.43 points across the two groups. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 35747889) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Huntington's Disease Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with Huntington's disease (HD) based on symptoms and family history, or confirmed through genetic testing showing a specific gene change linked to HD.
- Your HD symptoms are still relatively mild, based on a standard assessment score above 9 (confirm with trial site).
- You are able to walk around on your own and do not need professional nursing care.
- You are 16 years of age or older.
- If you are a woman, you are not able to become pregnant — either naturally (e.g., after menopause), through surgery, or by using reliable birth control throughout the study.
- If you take certain mental health medications (such as anti-anxiety, sleep, or antidepressant medications), your dose has been stable for at least four weeks before joining and should stay the same during the study if possible.
- You are able to understand and agree to the study procedures and give your consent to participate.
- You are able to swallow oral (by mouth) medication.
- You may need to have a trusted person (such as a family member or caregiver) who can help manage and supervise your daily medication at home.
- You agree to name someone who can make decisions on your behalf if your ability to give consent changes during the study.
Who may not be able to join:
- You have had a known bad reaction or sensitivity to Coenzyme Q10 (CoQ10) in the past.
- You have taken part in another clinical trial or used an experimental drug within the past 30 days.
- You have an unstable or serious physical health condition, as judged by the study doctor.
- You have experienced serious mental health symptoms such as hallucinations, delusions, untreated severe depression, or thoughts of suicide within the past 90 days.
- You have had a problem with alcohol or drug misuse within the past year.
- You are currently pregnant or breastfeeding.
- You have been taking CoQ10 supplements within the past 30 days.
- Your recent blood test results show certain serious abnormalities in kidney function, liver function, blood cell counts, or blood clotting (confirm specific values with trial site).
- You are allergic to a yellow food dye called FD&C Yellow #5, or to any other ingredient in the study medication.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Merit Cudkowicz, MD MSc, Massachusetts General Hospital
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Joint Rank (Combination of Time to Death (for Subjects Who Died) and Change in Total Functional Capacity Score (TFC) From Baseline to Month 60 (for Subjects Who Survived))
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.